Cargando…

High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019

BACKGROUND: The Danish National Patient Registry is a major resource for Danish epidemiology. Only a few studies have been conducted to check the validity of the reporting of systemic anticancer treatments. In this study, we assessed this validity for a range of cancer types over a long period of ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Vesteghem, Charles, Brøndum, Rasmus Froberg, Falkmer, Ursula G, Pottegård, Anton, Poulsen, Laurids Østergaard, Bøgsted, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628125/
https://www.ncbi.nlm.nih.gov/pubmed/34853537
http://dx.doi.org/10.2147/CLEP.S332776
_version_ 1784606955726176256
author Vesteghem, Charles
Brøndum, Rasmus Froberg
Falkmer, Ursula G
Pottegård, Anton
Poulsen, Laurids Østergaard
Bøgsted, Martin
author_facet Vesteghem, Charles
Brøndum, Rasmus Froberg
Falkmer, Ursula G
Pottegård, Anton
Poulsen, Laurids Østergaard
Bøgsted, Martin
author_sort Vesteghem, Charles
collection PubMed
description BACKGROUND: The Danish National Patient Registry is a major resource for Danish epidemiology. Only a few studies have been conducted to check the validity of the reporting of systemic anticancer treatments. In this study, we assessed this validity for a range of cancer types over a long period of time. PATIENTS AND METHODS: We extracted systemic anticancer treatment procedures from the Danish National Patient Registry for patients with solid malignant tumors treated at the Department of Oncology at Aalborg University Hospital between 2009 and 2019 (12,014 patients with 215,293 drug records). These data were compared to records obtained from the antineoplastic prescription database used at the department. We estimated the sensitivity, positive predictive value (PPV), and F1-score defined as the harmonic mean of the sensitivity and the PPV. RESULTS: There was an overall high concordance between the two datasets with a sensitivity and a PPV >92%. Treatments for brain, ovarian and endometrial cancers displayed lower concordance (81–89%). The validity was stable over the study period, with a slight drop during 2016–2017. Most drugs had a high validity with F1-scores above 90%. Fluorouracil, gemcitabine, pemetrexed, pembrolizumab, and nivolumab had F1-scores above 97%. Drugs that were introduced in the study period, such as lapatinib, palbociclib, erlotinib, pertuzumab, and panitumumab, yielded lower F1-scores due to the absence of specific registry codes early after introduction. CONCLUSION: The Danish National Patient Registry can be used to reliably obtain information about systemic anticancer treatments, keeping in mind limitations for recently introduced drugs and for some types of cancer.
format Online
Article
Text
id pubmed-8628125
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-86281252021-11-30 High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019 Vesteghem, Charles Brøndum, Rasmus Froberg Falkmer, Ursula G Pottegård, Anton Poulsen, Laurids Østergaard Bøgsted, Martin Clin Epidemiol Original Research BACKGROUND: The Danish National Patient Registry is a major resource for Danish epidemiology. Only a few studies have been conducted to check the validity of the reporting of systemic anticancer treatments. In this study, we assessed this validity for a range of cancer types over a long period of time. PATIENTS AND METHODS: We extracted systemic anticancer treatment procedures from the Danish National Patient Registry for patients with solid malignant tumors treated at the Department of Oncology at Aalborg University Hospital between 2009 and 2019 (12,014 patients with 215,293 drug records). These data were compared to records obtained from the antineoplastic prescription database used at the department. We estimated the sensitivity, positive predictive value (PPV), and F1-score defined as the harmonic mean of the sensitivity and the PPV. RESULTS: There was an overall high concordance between the two datasets with a sensitivity and a PPV >92%. Treatments for brain, ovarian and endometrial cancers displayed lower concordance (81–89%). The validity was stable over the study period, with a slight drop during 2016–2017. Most drugs had a high validity with F1-scores above 90%. Fluorouracil, gemcitabine, pemetrexed, pembrolizumab, and nivolumab had F1-scores above 97%. Drugs that were introduced in the study period, such as lapatinib, palbociclib, erlotinib, pertuzumab, and panitumumab, yielded lower F1-scores due to the absence of specific registry codes early after introduction. CONCLUSION: The Danish National Patient Registry can be used to reliably obtain information about systemic anticancer treatments, keeping in mind limitations for recently introduced drugs and for some types of cancer. Dove 2021-11-24 /pmc/articles/PMC8628125/ /pubmed/34853537 http://dx.doi.org/10.2147/CLEP.S332776 Text en © 2021 Vesteghem et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Vesteghem, Charles
Brøndum, Rasmus Froberg
Falkmer, Ursula G
Pottegård, Anton
Poulsen, Laurids Østergaard
Bøgsted, Martin
High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
title High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
title_full High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
title_fullStr High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
title_full_unstemmed High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
title_short High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
title_sort high validity of the danish national patient registry for systemic anticancer treatment registration from 2009 to 2019
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628125/
https://www.ncbi.nlm.nih.gov/pubmed/34853537
http://dx.doi.org/10.2147/CLEP.S332776
work_keys_str_mv AT vesteghemcharles highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019
AT brøndumrasmusfroberg highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019
AT falkmerursulag highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019
AT pottegardanton highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019
AT poulsenlauridsøstergaard highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019
AT bøgstedmartin highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019